Ligandrol (LGD-4033) 10 mg – 100 Capsules

Biochem Ligandrol (LGD-4033) 10 mg – 100 Capsules | Selective Androgen Receptor Modulator (SARM)

Biochem Ligandrol (LGD-4033) 10 mg – 100 Capsules is an oral capsule product containing ligandrol, also known as LGD-4033, VK5211, or LGD-4033 Ligandrol, a synthetic nonsteroidal selective androgen receptor modulator (SARM) developed for investigation of androgen receptor activity in skeletal muscle and bone.

This product contains 10 mg of ligandrol per capsule, with 100 capsules per package, representing 1,000 mg (1 gram) of ligandrol per package, based on the stated formulation.

Ligandrol belongs to a class of compounds known as selective androgen receptor modulators. These compounds are designed to interact with androgen receptors and influence biological processes regulated by androgen signaling.

Androgen receptors are intracellular nuclear receptors involved in skeletal muscle physiology, bone metabolism, reproductive function, and numerous other androgen-responsive processes.

Unlike traditional anabolic-androgenic steroids, ligandrol does not possess the classical steroidal chemical structure found in testosterone-derived compounds.

Instead, ligandrol is a synthetic nonsteroidal molecule that binds to androgen receptors and influences receptor-mediated gene transcription.

Ligandrol was developed as a potential therapeutic compound for conditions involving muscle loss, impaired physical function, and altered musculoskeletal physiology.

Early clinical development investigated its effects on lean body mass, hormone concentrations, tolerability, and other physiological measurements.

A short-term randomized human study reported increases in lean body mass at certain investigated exposures. However, the study did not establish meaningful improvements in functional strength or long-term clinical outcomes.

Ligandrol has also been studied in clinical development programs involving patients recovering from hip fractures.

These investigations do not establish ligandrol as an approved treatment for muscle wasting, osteoporosis, sarcopenia, fracture recovery, or other musculoskeletal conditions.

Although ligandrol is often discussed in bodybuilding and athletic performance contexts, adequate clinical evidence does not establish that it safely improves strength, endurance, recovery, or physical performance in healthy individuals.

Human studies have identified changes in endogenous testosterone concentrations, sex hormone-binding globulin, and lipid-related measurements.

These observations demonstrate that tissue-selective androgen receptor modulation does not eliminate the possibility of systemic endocrine effects.

Additional concerns associated with SARMs include potential liver injury, adverse lipid changes, reproductive effects, and uncertain long-term cardiovascular safety.

Ligandrol is not testosterone, recombinant growth hormone, a peptide hormone, or a conventional anabolic-androgenic steroid.

Its chemical structure and receptor activity distinguish it from compounds such as ibutamoren (MK-677), which acts primarily through the ghrelin receptor, and cardarine (GW-501516), which acts primarily through PPARδ.

Ligandrol is prohibited in competitive sport under World Anti-Doping Agency rules.

The Biochem brand name does not independently establish pharmaceutical approval, manufacturing quality, analytical purity, or clinical suitability.

1. Selectively Interacts With Androgen Receptors

Ligandrol is a synthetic nonsteroidal compound developed to bind to androgen receptors.

Androgen receptors are nuclear proteins that regulate gene expression in response to androgenic signaling.

Following ligand binding, androgen receptors can undergo conformational changes that influence interactions with transcriptional regulatory proteins.

The resulting biological effects depend on tissue characteristics, receptor expression, and the pharmacological properties of the compound.

2. Was Developed for Tissue-Selective Androgen Receptor Activity

The development of SARMs was motivated by the possibility of influencing selected androgen-responsive tissues without reproducing every effect associated with traditional anabolic-androgenic steroids.

Ligandrol was investigated particularly for its potential effects on skeletal muscle and musculoskeletal function.

However, tissue selectivity does not mean that ligandrol acts exclusively in muscle or bone.

Human studies have demonstrated endocrine changes, illustrating that systemic biological effects remain possible.

3. Has Been Investigated in Lean Body Mass Research

Androgen receptor signaling contributes to skeletal muscle protein metabolism and tissue maintenance.

In an early randomized human study, ligandrol exposure was associated with dose-related increases in lean body mass over a short investigation period.

However, changes in lean body mass do not necessarily establish improvements in muscle strength, endurance, mobility, or other functional outcomes.

These observations do not justify claims of proven muscle-building effectiveness or safety in healthy individuals.

4. Has Been Investigated in Musculoskeletal Recovery

Ligandrol entered clinical development programs examining muscle-related outcomes in selected patient populations.

Research has included investigations involving recovery following hip fracture.

Such studies were intended to evaluate whether androgen receptor modulation could influence body composition and physical function.

These investigations have not established an approved clinical indication for ligandrol.

5. Differs Chemically From Anabolic-Androgenic Steroids

Ligandrol does not contain the classical steroid nucleus characteristic of testosterone and many anabolic-androgenic steroids.

Nevertheless, it interacts with androgen receptors and can influence endocrine physiology.

A nonsteroidal chemical structure should not be interpreted as evidence that a compound cannot suppress endogenous hormone production or produce androgen-related adverse effects.

6. Has Been Evaluated in Human Pharmacokinetic Studies

Early human investigations demonstrated that ligandrol is orally active.

Published clinical research has reported an elimination half-life on the order of approximately 24–36 hours, although pharmacokinetic measurements depend on study conditions.

These observations do not independently establish the absorption, exposure, or elimination characteristics of a particular commercial capsule formulation.

The exact pharmacokinetic profile of Biochem Ligandrol 10 mg has not been independently verified.

7. Has Important Endocrine, Metabolic, and Long-Term Safety Concerns

Human studies have identified changes in testosterone concentrations, sex hormone-binding globulin, and HDL cholesterol.

Potential additional concerns include liver injury, reproductive effects, adverse lipid changes, and uncertain cardiovascular risks.

Long-term human safety data are insufficient to determine the frequency, severity, or reversibility of many possible adverse effects.

Ligandrol has no established approved therapeutic indication for muscle growth, athletic performance, recovery, osteoporosis, sarcopenia, or hormone replacement.

The 10 mg capsule strength describes the product presentation and does not establish a medically validated or safe human dose.

Step 1 – Oral Capsule Administration and Absorption

Ligandrol is an orally active nonsteroidal androgen receptor modulator.

Following oral administration, the compound can be absorbed through the gastrointestinal tract and enter systemic circulation.

The absorption characteristics of this specific Biochem capsule formulation have not been independently established.

Step 2 – Distribution to Androgen-Responsive Tissues

Following absorption, ligandrol may distribute to tissues containing androgen receptors.

Potential target tissues include skeletal muscle, bone, and other androgen-responsive organs.

The tissue distribution of the requested Biochem formulation has not been independently established.

Step 3 – Interaction With Androgen Receptors

Ligandrol binds to androgen receptors and influences receptor-associated signaling.

The resulting receptor conformation can affect interactions with transcriptional regulatory proteins.

These interactions are involved in the regulation of androgen-responsive gene expression.

Step 4 – Modulation of Gene Transcription

Androgen receptor signaling can influence genes involved in tissue metabolism, cellular regulation, and musculoskeletal physiology.

The biological consequences depend on tissue characteristics and individual endocrine conditions.

Preclinical observations and short-term human biomarker changes cannot independently establish long-term clinical benefits.

Step 5 – Metabolism and Elimination

Following systemic exposure, ligandrol undergoes metabolic processing and elimination.

Early human pharmacokinetic research provides information about its systemic persistence, but the complete metabolic and elimination characteristics of this Biochem capsule formulation have not been verified.

The Biochem Ligandrol 10 mg capsule presentation includes the following characteristics:

• Ligandrol (LGD-4033) as the stated active compound.
• Alternative development designation VK5211.
• 10 mg per capsule.
• 100 capsules per package.
• 1,000 mg total stated active ingredient content.
• Oral capsule presentation.
• Nonsteroidal chemical classification.
• Selective androgen receptor modulator classification.
• Androgen receptor-binding activity.
• Modulation of androgen-responsive gene transcription.
• Investigation of skeletal muscle physiology.
• Investigation of lean body mass changes.
• Early controlled human clinical research.
• Clinical development involving musculoskeletal recovery.
• No established approved human therapeutic indication.
• No validated safe human dosing regimen.
• Reported endocrine changes in clinical studies.
• Reported HDL cholesterol changes.
• Potential suppression of endogenous reproductive hormone signaling.
• Potential liver-related adverse effects.
• Inadequately characterized long-term cardiovascular safety.
• No established clinical benefit for athletic performance.
• Prohibited status under WADA rules.
• Capsule excipients requiring confirmation.
• Identity, purity, and content uniformity requiring independent analytical verification.

The precise excipient composition, capsule appearance, manufacturing specifications, purity, and analytical content of Biochem Ligandrol 10 mg have not been independently verified.

The stated package contains 100 capsules of 10 mg each, representing 1,000 mg total stated active ingredient.

This description does not establish regulatory authorization, clinical safety, or suitability for human administration.

United States

Biochem Ligandrol 10mg, Biochem LGD4033 10mg, Ligandrol 10mg 100 capsules, LGD4033 100 capsules, Ligandrol United States, Ligandrol selective androgen receptor modulator, LGD4033 SARM compound, Ligandrol molecular formula, Ligandrol chemical structure, LGD4033 androgen receptor activity, Ligandrol pharmacology, Ligandrol clinical studies, LGD4033 lean body mass research, Ligandrol muscle physiology, Ligandrol hormone suppression, LGD4033 safety concerns, Ligandrol clinical evidence, Ligandrol capsule specifications.

Canada

English: Biochem Ligandrol 10mg Canada, LGD4033 10mg Canada, Ligandrol 100 capsules, Ligandrol SARM, selective androgen receptor modulator, Ligandrol properties, LGD4033 pharmacology, Ligandrol molecular structure, LGD4033 androgen receptor, Ligandrol clinical research, LGD4033 lean body mass, Ligandrol endocrine effects, LGD4033 safety information, Ligandrol clinical evidence.

French: Biochem Ligandrol 10 mg Canada, LGD4033 10 mg, Ligandrol 100 capsules, modulateur sélectif des récepteurs aux androgènes, propriétés du ligandrol, pharmacologie du LGD4033, récepteur aux androgènes, structure moléculaire, études cliniques, masse corporelle maigre, physiologie musculaire, effets endocriniens, suppression hormonale, informations de sécurité, données cliniques limitées.

United Kingdom

Biochem Ligandrol 10mg UK, Ligandrol LGD4033 UK, Ligandrol 100 capsules, selective androgen receptor modulator, LGD4033 SARM, Ligandrol pharmacology, Ligandrol chemical structure, LGD4033 androgen receptor binding, Ligandrol clinical studies, Ligandrol lean body mass research, LGD4033 muscle physiology, Ligandrol hormonal effects, LGD4033 safety profile, Ligandrol clinical evidence.

Germany

Biochem Ligandrol 10 mg Deutschland, Ligandrol LGD4033, Ligandrol 100 Kapseln, selektiver Androgenrezeptormodulator, SARM Ligandrol, Ligandrol Eigenschaften, LGD4033 Wirkungsmechanismus, Androgenrezeptor, Ligandrol Molekülstruktur, klinische Studien, fettfreie Körpermasse, Muskelphysiologie, hormonelle Veränderungen, Sicherheitsinformationen, begrenzte klinische Daten.

France

Biochem Ligandrol 10 mg France, Ligandrol LGD4033, Ligandrol 100 gélules, modulateur sélectif des récepteurs aux androgènes, SARM Ligandrol, propriétés du ligandrol, mécanisme d'action du LGD4033, récepteur aux androgènes, structure moléculaire, études cliniques, masse maigre, physiologie musculaire, effets hormonaux, informations de sécurité, données cliniques limitées.

Spain

Biochem Ligandrol 10 mg España, Ligandrol LGD4033, Ligandrol 100 cápsulas, modulador selectivo del receptor de andrógenos, SARM Ligandrol, propiedades del ligandrol, mecanismo de acción del LGD4033, receptor de andrógenos, estructura molecular, estudios clínicos, masa corporal magra, fisiología muscular, efectos hormonales, información de seguridad, evidencia clínica limitada.

Italy

Biochem Ligandrol 10 mg Italia, Ligandrol LGD4033, Ligandrol 100 capsule, modulatore selettivo del recettore degli androgeni, SARM Ligandrol, proprietà del ligandrol, meccanismo d'azione LGD4033, recettore degli androgeni, struttura molecolare, studi clinici, massa magra, fisiologia muscolare, effetti ormonali, informazioni di sicurezza, dati clinici limitati.

Portugal

Biochem Ligandrol 10 mg Portugal, Ligandrol LGD4033, Ligandrol 100 cápsulas, modulador seletivo dos recetores de androgénios, SARM Ligandrol, propriedades do ligandrol, mecanismo de ação do LGD4033, recetor de androgénios, estrutura molecular, estudos clínicos, massa corporal magra, fisiologia muscular, efeitos hormonais, informações de segurança, evidência clínica limitada.

Netherlands

Biochem Ligandrol 10 mg Nederland, Ligandrol LGD4033, Ligandrol 100 capsules, selectieve androgeenreceptormodulator, SARM Ligandrol, eigenschappen van ligandrol, werkingsmechanisme LGD4033, androgeenreceptor, moleculaire structuur, klinische studies, vetvrije massa, spierfysiologie, hormonale effecten, veiligheidsinformatie, beperkte klinische gegevens.

Belgium

Biochem Ligandrol 10 mg België, Ligandrol 10 mg Belgique, Ligandrol LGD4033, Ligandrol 100 capsules, selectieve androgeenreceptormodulator, modulateur sélectif des récepteurs aux androgènes, SARM Ligandrol, eigenschappen van ligandrol, propriétés du ligandrol, androgeenreceptor, récepteur aux androgènes, klinische studies, études cliniques, hormonale effecten, effets hormonaux, veiligheidsinformatie.

Switzerland

Biochem Ligandrol 10 mg Schweiz, Ligandrol 10 mg Suisse, Ligandrol LGD4033, Ligandrol 100 Kapseln, Ligandrol 100 gélules, selektiver Androgenrezeptormodulator, modulateur sélectif des récepteurs aux androgènes, SARM Ligandrol, Androgenrezeptor, récepteur aux androgènes, klinische Studien, études cliniques, hormonelle Veränderungen, effets hormonaux, Sicherheitsinformationen.

Austria

Biochem Ligandrol 10 mg Österreich, Ligandrol LGD4033, Ligandrol 100 Kapseln, selektiver Androgenrezeptormodulator, SARM Ligandrol, Ligandrol Eigenschaften, LGD4033 Wirkungsmechanismus, Androgenrezeptor, Molekülstruktur, klinische Forschung, fettfreie Körpermasse, Muskelphysiologie, hormonelle Veränderungen, Sicherheitsinformationen, begrenzte klinische Daten.

Sweden

Biochem Ligandrol 10 mg Sverige, Ligandrol LGD4033, Ligandrol 100 kapslar, selektiv androgenreceptormodulator, SARM Ligandrol, ligandrol egenskaper, LGD4033 verkningsmekanism, androgenreceptor, molekylstruktur, kliniska studier, fettfri kroppsmassa, muskelfysiologi, hormonella effekter, säkerhetsinformation, begränsade kliniska data.

Norway

Biochem Ligandrol 10 mg Norge, Ligandrol LGD4033, Ligandrol 100 kapsler, selektiv androgenreseptormodulator, SARM Ligandrol, ligandrol egenskaper, LGD4033 virkningsmekanisme, androgenreseptor, molekylstruktur, kliniske studier, fettfri kroppsmasse, muskelfysiologi, hormonelle effekter, sikkerhetsinformasjon, begrensede kliniske data.

Denmark

Biochem Ligandrol 10 mg Danmark, Ligandrol LGD4033, Ligandrol 100 kapsler, selektiv androgenreceptormodulator, SARM Ligandrol, ligandrol egenskaber, LGD4033 virkningsmekanisme, androgenreceptor, molekylstruktur, kliniske studier, fedtfri kropsmasse, muskelfysiologi, hormonelle effekter, sikkerhedsinformation, begrænsede kliniske data.

Finland

Biochem Ligandrol 10 mg Suomi, Ligandrol LGD4033, Ligandrol 100 kapselia, selektiivinen androgeenireseptorin muuntelija, SARM Ligandrol, ligandrolin ominaisuudet, LGD4033 vaikutusmekanismi, androgeenireseptori, molekyylirakenne, kliiniset tutkimukset, rasvaton kehonmassa, lihasfysiologia, hormonaaliset vaikutukset, turvallisuustiedot, rajallinen kliininen näyttö.

Poland

Biochem Ligandrol 10 mg Polska, Ligandrol LGD4033, Ligandrol 100 kapsułek, selektywny modulator receptora androgenowego, SARM Ligandrol, właściwości ligandrolu, mechanizm działania LGD4033, receptor androgenowy, struktura molekularna, badania kliniczne, beztłuszczowa masa ciała, fizjologia mięśni, zmiany hormonalne, informacje o bezpieczeństwie, ograniczone dane kliniczne.

Czech Republic

Biochem Ligandrol 10 mg Česko, Ligandrol LGD4033, Ligandrol 100 kapslí, selektivní modulátor androgenového receptoru, SARM Ligandrol, vlastnosti ligandrolu, mechanismus účinku LGD4033, androgenový receptor, molekulární struktura, klinické studie, beztuková tělesná hmota, svalová fyziologie, hormonální účinky, bezpečnostní informace, omezené klinické údaje.

Romania

Biochem Ligandrol 10 mg România, Ligandrol LGD4033, Ligandrol 100 capsule, modulator selectiv al receptorilor androgenici, SARM Ligandrol, proprietăți ligandrol, mecanism de acțiune LGD4033, receptor androgenic, structură moleculară, studii clinice, masă corporală slabă, fiziologie musculară, efecte hormonale, informații de siguranță, date clinice limitate.

Greece

Biochem Ligandrol 10 mg Ελλάδα, λιγκανδρόλη LGD4033, Ligandrol 100 κάψουλες, εκλεκτικός τροποποιητής υποδοχέων ανδρογόνων, SARM Ligandrol, ιδιότητες λιγκανδρόλης, μηχανισμός δράσης LGD4033, υποδοχέας ανδρογόνων, μοριακή δομή, κλινικές μελέτες, άλιπη σωματική μάζα, μυϊκή φυσιολογία, ορμονικές επιδράσεις, πληροφορίες ασφάλειας, περιορισμένα κλινικά δεδομένα.

Ireland

Biochem Ligandrol 10mg Ireland, Ligandrol LGD4033 Ireland, Ligandrol 100 capsules, selective androgen receptor modulator, LGD4033 SARM, Ligandrol pharmacology, Ligandrol molecular structure, LGD4033 androgen receptor activity, Ligandrol clinical studies, Ligandrol lean body mass research, LGD4033 muscle physiology, Ligandrol hormonal effects, LGD4033 safety information, limited long-term human evidence.

Colombia

Biochem Ligandrol 10 mg Colombia, Ligandrol LGD4033 Colombia, Ligandrol 100 cápsulas, ligandrol 10 mg, modulador selectivo del receptor de andrógenos, SARM ligandrol, propiedades del ligandrol, cómo funciona el LGD4033, farmacología del ligandrol, receptor de andrógenos, estructura molecular, estudios clínicos, masa corporal magra, fisiología muscular, efectos hormonales, información de seguridad, evidencia clínica limitada.

Argentina

Biochem Ligandrol 10 mg Argentina, Ligandrol LGD4033 Argentina, Ligandrol 100 cápsulas, ligandrol 10 mg, modulador selectivo del receptor de andrógenos, SARM ligandrol, propiedades del ligandrol, qué es el LGD4033, mecanismo de acción del ligandrol, receptor androgénico, estructura molecular, estudios clínicos, masa magra, fisiología muscular, cambios hormonales, información de seguridad.

México

Biochem Ligandrol 10 mg México, Ligandrol LGD4033 México, Ligandrol 100 cápsulas, ligandrol 10 mg, modulador selectivo del receptor de andrógenos, SARM Ligandrol, propiedades del ligandrol, para qué se investigó el LGD4033, cómo funciona el ligandrol, farmacología del LGD4033, receptor de andrógenos, estructura molecular, estu